NCT01330823

L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)

L-Carnitine in the Palliative Treatment of Advanced Pancreatic Cancer (CARPAN): a Prospective, Randomised, Placebo Controlled, Double Blinded, Multicentre Trial

• Status: Suspended
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: University Medicine Greifswald · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, UICC Stage IV .

Detailed description

Pancreatic cancer has the lowest 5-year survival rate of any cancer and ranks as the fourth leading cause of cancer death world wide. Several metabolic changes are present in the whole body in case of cancer so the investigators conducted a placebo controlled, double blinded, randomized, prospective and multicentre study to investigate, whether L-Carnitine supplementation may have an impact on malnutrition, cancer cachexia and cancer related fatigue in advanced pancreatic cancer. Study drug: L-Carnitine 4g per day (vers) Placebo Study design: A multi-centre, double blind, and placebo-controlled, randomised, parallel group study Patient population: Patients with advanced pancreatic carcinoma Number of patients: Total of 90 patients in two equal groups number of centres: 4 (Greifswald, Magdeburg, Berlin,Heidelberg,all Germany) Duration of dosing: 12 weeks

Conditions

• Pancreatic Carcinoma

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	L-Carnitine	L-Carnitine, 4g/day, orally (Juice)
DIETARY_SUPPLEMENT	Placebo	tartaric acid same dose like L-Carnitine as placebo

Timeline

• Start date: 2006-06-01
• Primary completion: 2009-10-01
• Completion: 2010-07-01
• First posted: 2011-04-07
• Last updated: 2011-04-07

Locations

1 site across 1 country: Germany